UBS Upgrades Lincare to Buy

The therapy provider's stock rose after the government recommended a higher dispensing fee for respiratory therapies

UBS Financial upgraded Lincare (LNCR ) to buy from neutral.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.